The significant and growing global prevalence of diabetes continues to challenge people
with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal …

Improvements in sensor accuracy, greater convenience and ease of use, and expanding
reimbursement have led to growing adoption of continuous glucose monitoring (CGM) …

Background Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved
by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) …

Background In persons with type 1 diabetes and high glycated hemoglobin levels, the
benefits of intermittently scanned continuous glucose monitoring with optional alarms for …

An open-label, first-in-human phase 1/2 study is being conducted to evaluate the safety and
efficacy of pancreatic endoderm cells (PECs) implanted in non-immunoprotective …

Background Closed-loop control systems of insulin delivery may improve glycemic
outcomes in young children with type 1 diabetes. The efficacy and safety of initiating a …

Background Currently available semiautomated insulin-delivery systems require
individualized insulin regimens for the initialization of therapy and meal doses based on …

Background The possible advantage of hybrid closed-loop therapy (ie, artificial pancreas)
over sensor-augmented pump therapy in very young children with type 1 diabetes is …

We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic
function and immune cells among participants in a previously reported randomized …

Background: The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL)
algorithm that provides both automated basal and correction bolus insulin delivery. The …